Autres langues CStone Pharmaceuticals

Actions

2616

KYG2588M1006

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:02 04/07/2024			Varia. 5j.	Varia. 1 janv.
1,16 ^HKD	+3,57 %		+4,50 %	-48,90 %

03/07	CStone Pharmaceuticals accorde à Jiangsu Hengrui Medicine les droits exclusifs de promotion d'un médicament contre les tumeurs en Chine	MT
03/07	Annonce volontaire - CStone Pharmaceuticals et Jiangsu Hengrui Pharmaceuticals Co., Ltd concluent un accord de promotion exclusive d'AYVAKIT® (comprimés d'avapritinib) en Chine continentale	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine	03/07
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China	03/07
CStone Pharmaceuticals Announces Change of Joint Company Secretary	18/06
CStone Gets Green Light for Local Manufacturing of AYVAKIT in China	13/06
CStone Pharma Presents Cancer Drug Study Data at US Oncology Society Meeting	04/06
CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024	04/06
European Regulators Recommend CStone Pharmaceuticals’ Sugemalimab for Approval, Shares Up 13%	03/06
Cstone Pharmaceuticals Announces CHMP of the European Medicine Agency Recommends Approval of Cejemly (Sugemalimab, Anti-Pd-L1) as First-Line Treatment for NSCLC	03/06
CStone Pharmaceuticals to License Anti-Cancer Drug in 19 European Countries	27/05
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website	24/05
CStone to Present CS5001 Phase I Results at 2024 ASCO Annual Meeting	06/05
Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO	06/05
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25%	02/05
Cstone Pharmaceuticals’ CEO Boosts Stakeholding	29/04
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	24/04
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	23/04
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	09/04
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	09/04
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved	15/03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer	15/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CStone Pharmaceuticals

Actions

2616

KYG2588M1006

Autres langues

Filtres